Abstract
Cancer cachexia, one of the metabolic syndromes caused by cancer, is a devastating and miserable condition encountered in more than 50% of terminal cancer patients presenting with significant weight loss associated with skeletal muscle atrophy and fat loss. Though cachexia may account for up to 20% of cancer deaths, no significant treatment is still lacking and is of urgent unmet medical need in cancer treatment. Therefore, understanding the underlying molecular mechanisms is essential for anticipating therapeutic approaches. Since the primary events driving cachexia are mediated via either the central nervous system relatedor inflammation related-anorexia, hypoanabolism, and hypercatabolism, therapy usually targets nutritional support to compensate reduced food intake along with some anti-inflammatory agents to cover specific inflammation-related metabolic derangement, and encourages exercise to supplement reduced physical activity, but all proven to be not so effective so far. Therefore, combination therapies such as a standard multi-modal package including an anorexic agent, megestrol acetate, and anti-inflammatory agent coupled with the development of potential novel therapeutics promise a new era in rescuing patients from cancer cachexia. In this review, we propose the potential application of BPC157, one of the active cytoprotective agents isolated from gastric juices for cancer cachexia. Before clinical trial, we introduced the evidence showing BPC157 rescued from cancer cachexia supported with explored mode of actions.
Keywords: Cancer cachexia, BPC157, muscle atrophy, cytoprotection, hypercatabolism, hypoanabolism.
Current Pharmaceutical Design
Title:BPC157 as Potential Agent Rescuing from Cancer Cachexia
Volume: 24 Issue: 18
Author(s): Eun A. Kang, Young-Min Han, Jeong Min An, Yong Jin Park, Predrag Sikiric, Deok Hwan Kim, Kwang An Kwon, Yoon Jae Kim, Donghwa Yang, Hann Tchah and Ki Baik Hahm*
Affiliation:
- Digestive Disease Center, CHA University Bundang Medical Center, Seongnam,Korea
Keywords: Cancer cachexia, BPC157, muscle atrophy, cytoprotection, hypercatabolism, hypoanabolism.
Abstract: Cancer cachexia, one of the metabolic syndromes caused by cancer, is a devastating and miserable condition encountered in more than 50% of terminal cancer patients presenting with significant weight loss associated with skeletal muscle atrophy and fat loss. Though cachexia may account for up to 20% of cancer deaths, no significant treatment is still lacking and is of urgent unmet medical need in cancer treatment. Therefore, understanding the underlying molecular mechanisms is essential for anticipating therapeutic approaches. Since the primary events driving cachexia are mediated via either the central nervous system relatedor inflammation related-anorexia, hypoanabolism, and hypercatabolism, therapy usually targets nutritional support to compensate reduced food intake along with some anti-inflammatory agents to cover specific inflammation-related metabolic derangement, and encourages exercise to supplement reduced physical activity, but all proven to be not so effective so far. Therefore, combination therapies such as a standard multi-modal package including an anorexic agent, megestrol acetate, and anti-inflammatory agent coupled with the development of potential novel therapeutics promise a new era in rescuing patients from cancer cachexia. In this review, we propose the potential application of BPC157, one of the active cytoprotective agents isolated from gastric juices for cancer cachexia. Before clinical trial, we introduced the evidence showing BPC157 rescued from cancer cachexia supported with explored mode of actions.
Export Options
About this article
Cite this article as:
Kang A. Eun, Han Young-Min, An Min Jeong , Park Jin Yong , Sikiric Predrag , Kim Hwan Deok , Kwon An Kwang , Kim Jae Yoon , Yang Donghwa , Tchah Hann and Hahm Baik Ki *, BPC157 as Potential Agent Rescuing from Cancer Cachexia, Current Pharmaceutical Design 2018; 24 (18) . https://dx.doi.org/10.2174/1381612824666180614082950
DOI https://dx.doi.org/10.2174/1381612824666180614082950 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Spirulina paltensis: Food and Function
Current Nutrition & Food Science Patent Selections
Recent Patents on Drug Delivery & Formulation Ascorbic Acid in Cancer Chemoprevention: Translational Perspectives and Efficacy
Current Drug Targets Mutations in MicroRNA Genes and Their Binding Sites are Infrequently Associated with Human Colorectal Cancer in the Kashmiri Population
MicroRNA The Urokinase Plasminogen Activator System: Role in Malignancy
Current Pharmaceutical Design miRNA-497 Enhances the Sensitivity of Colorectal Cancer Cells to Neoadjuvant Chemotherapeutic Drug
Current Protein & Peptide Science Update on the Regulation of HIPK1, HIPK2 and HIPK3 Protein Kinases by microRNAs
MicroRNA Chemical Biology: Past, Present and Future
Current Chemical Biology Nitric Oxide-NASIDS Donor Prodrugs as Hybrid Safe Anti-inflammatory Agents
Current Topics in Medicinal Chemistry Pharmaceutical Approaches for Optimizing Oral Anti-Inflammatory Delivery Systems
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry <i>Crocus Sativus</i> L. (Saffron) in Alzheimer’s Disease Treatment: Bioactive Effects on Cognitive Impairment
Current Neuropharmacology Cancer: A Problem of Developmental Biology; Scientific Evidence for Reprogramming and Differentiation Therapy
Current Drug Targets Endocrinology and Immunology of Obesity, Obesity Vaccines
Current Clinical Pharmacology Synthesis of Novel 2,3,4-trisubstituted-oxazolidine Derivatives and In Vitro Cytotoxic Evaluation
Medicinal Chemistry Raman Spectroscopy and Imaging: Promising Optical Diagnostic Tools in Pediatrics
Current Medicinal Chemistry Targeting Apoptosis Pathway with Natural Terpenoids: Implications for Treatment of Breast and Prostate Cancer
Current Drug Targets Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Chitosan - A Potential Polymer to Prepare Anticancer Drug Delivery Systems: Patent Review
Recent Patents on Anti-Cancer Drug Discovery Genetic Mechanisms and Aberrant Gene Expression during the Development of Gastric Intestinal Metaplasia and Adenocarcinoma
Current Genomics Reactive Oxygen and Nitrogen Species in Carcinogenesis: Implications of Oxidative Stress on the Progression and Development of Several Cancer Types
Mini-Reviews in Medicinal Chemistry